Results 21 to 30 of about 13,388,853 (301)

DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage. [PDF]

Diabetes, 2023
Microvascular pathology in the brain is one of the suggested mechanisms underlying the increased incidence and progression of neurodegenerative diseases in people with type 2 diabetes (T2D).
Elabi OF, Karampatsi D, Vercalsteren E, Lietzau G, Nyström T, Klein T, Darsalia V, Patrone C, Paul G.   +8 more
europepmc   +2 more sources

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes

Frontiers in Endocrinology, 2020
Objective: We recently observed a greater increase in plasma levels of bioactive glucose-dependent insulinotropic polypeptide (GIP) than glucagon-like peptide 1 (GLP-1) using the receptor-mediated bioassays in the subjects with normal glycemic tolerance (
Tsuyoshi Yanagimachi, Yukihiro Fujita, Yukihiro Fujita, Yasutaka Takeda, Jun Honjo, Jun Honjo, Hiroki Yokoyama, Masakazu Haneda   +7 more
doaj   +1 more source

Characterization of Schnurri : an integral component of the Dpp-signaling pathway in "Drosophila melanogaster" [PDF]

, 2004
Signaling by the transforming growth factor-β (TGF-β) family of ligands plays a crucial role during development and tissue homeostasis in all multicellular organisms. The signal transduction pathway is highly conserved and relatively simple.
Hartmann, Britta
core   +1 more source

All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes

BMC Endocrine Disorders, 2019
Background Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA1C and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia.
Fu-Shun Yen, Jen-Huai Chiang, Chii-Min Hwu, Yu-Hsin Yen, Boniface J. Lin, James Cheng-Chung Wei, Chih-Cheng Hsu   +6 more
doaj   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Clinical Case Reports, 2020
We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara, Toshie Iijima, Shintaro Sakurai, Teruo Jojima, Eriko Ohira, Shujiro Hayashi, Isao Usui, Ken Igawa, Yoshimasa Aso   +8 more
doaj   +1 more source

DPP-4 mediating insulin resistance and lipogenesis.

, 2022
HepG2 cells were incubated with OAPA and 50 μM of linagliptin for 24 h, and then analyzed the cytotoxicity (A), DPP-4 activity (B), the expression of FAS (C) and insulin resistance (D) signals. For the cytotoxicity and DPP-4 activity, data were presented
Yaw-Bee Ker (515378), Chien-Ning Huang (1739806), Sing-Hua Tsou (12245366), Chih-Li Lin (205951), Chiung-Huei Peng (1739797), Hsin-Hua Li (6876338)   +5 more
core   +1 more source

The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known.
Masanori Hirose, Hiroyuki Takano, Hiroshi Hasegawa, Hiroyuki Tadokoro, Naoko Hashimoto, Genzo Takemura, Yoshio Kobayashi   +6 more
doaj   +1 more source

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU).
Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi   +9 more
doaj   +1 more source

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study

Frontiers in Endocrinology, 2021
AimAt present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed.
Junpei Sanada, Tomohiko Kimura, Masashi Shimoda, Akiko Tomita, Yoshiro Fushimi, Tomoe Kinoshita, Atsushi Obata, Seizo Okauchi, Hidenori Hirukawa, Kenji Kohara, Fuminori Tatsumi, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto   +14 more
doaj   +1 more source

Regulation of Dpp target genes by Mad/Medea and Brinker [PDF]

, 2009
The TGF-β family member Decapentaplegic (Dpp) is a key regulator of patterning and growth in development of Drosophila. Binding of Dpp to its receptors triggers the activation of the intracellular Smad pathway.
Weiss, Alexander
core   +1 more source